Amgen
Nasdaq AMGN · Thousand Oaks, CA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Amgen is a clinical trial sponsor based in Thousand Oaks, CA, listed as Nasdaq AMGN. It has 101 active clinical trials with 82,709 planned participants, across 15 therapeutic areas. Since 2021 it has completed 360 trials and stopped 79 early.
Trial track record · since 2021
Financials · Nasdaq AMGN
Pipeline · 101 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
24 approved drug applications with a product on the market.
Questions about Amgen
Amgen is lead sponsor of 101 active clinical trials on ClinicalTrials.gov, with 82,709 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 360 trials and stopped 79 early.
Amgen is based in Thousand Oaks, CA and is listed as Nasdaq AMGN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Amgen; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Amgen. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.